City

Iowa City (2)

Philadelphia (2)

Buffalo (1)

Little Rock (1)

Rome (1)

Condition

Neuroendocrine Tumor Grade 2 (5)

Neuroendocrine Tumor Grade 1 (3)

Neuroendocrine Tumors (3)

Liver Metastases (1)

Neuroendocrine Carcinoma (1)

Neuroendocrine Neoplasm (1)

Neuroendocrine Tumor of Pancreas (1)

Neuroendocrine Tumor of the Lung (1)

Overall Status

Recruiting (4)

Enrolling by invitation (1)

Phase

early phase 1 (2)

phase 2 (2)

Sponsor

Abramson Cancer Center of the University of Pennsylvania (2)

David Bushnell (1)

University of Roma La Sapienza (1)

Yusuf Menda (1)

Collaborator

CARTI (2)

Holden Comprehensive Cancer Center (2)

National Cancer Institute (NCI) (2)

Roswell Park Cancer Institute (2)

Perspective Therapeutics (1)

Viewpoint Molecular Targeting (1)

Intervention

[203pb] vmt-α-net spect/ct (1)

[203pb]vmt-α-net (1)

[212pb] vmt-α-net (1)

capecitabine oral product (1)

capecitabine tablets + temozolomide tablets + sir-spheres (1)

somatostatin analog; chemotherapy (1)

spect/ct (1)

temozolomide oral product (1)

transarterial radioembolization (1)

Study Documents

Intervention Type

drug (4)

combination product (2)

device (1)

diagnostic test (1)

Funder Type

Other (5)

Study Type

Interventional (4)

Observational (1)

neuroendocrine tumor grade 2

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1 Trial in Iowa City ([212Pb] VMT-a-NET,

Recruiting

Neuroendocrine Tumors
+4 more

[212Pb] VMT-α-NET
[203Pb] VMT-α-NET SPECT/CT

Iowa City, Iowa

Holden Comprehensive Cancer Center at the University of Iowa

Nov 30, 2023